Benefits and risks of erythrocyte-stimulating agents

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 3, Issue 3

This Article

Academic Content and Language Evaluation of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

All Articles published online

Item

Count

PDF

374

WORD

312

HTML

4495

Tables (1-5)

186

Sum=5367

Publishing Process of This Article

Item

Count

Browse

974

Download

1035

Sum=2009

Nov 24, 2014 (publication date) through Nov 6, 2024

Times Cited of This Article

Journal Information of This Article

Publication Name

World Journal of Clinical Urology

ISSN

2219-2816

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Review

World J Clin Urol. Nov 24, 2014; 3(3): 258-263
Published online Nov 24, 2014. doi: 10.5410/wjcu.v3.i3.258

Table 4 Nonhematologic complications associated with erythropoietin therapy[11]

Citation: Katagiri D, Hinoshita F. Benefits and risks of erythrocyte-stimulating agents. World J Clin Urol 2014; 3(3): 258-263
URL: https://www.wjgnet.com/2219-2816/full/v3/i3/258.htm
DOI: https://dx.doi.org/10.5410/wjcu.v3.i3.258